Market Cap:
Price Delay ~20min
Entitlement Offer Prospectus
May/June 2020

Presentations & Interviews

    Corporate Presentation for the Reach Markets Virtual Event  
    Webcast Overview of ASCO 2020 Annual Meeting NOX Posters  
    Updated Noxopharm Virtual Roadshow Corporate Presentation  
    Noxopharm Virtual Roadshow Corporate Presentation  
    Noxopharm Corporate Presentation February 2020  
    Noxopharm (ASX:NOX) LuPIN trial in prostate cancer  
    Noxopharm Non-Deal Roadshow Presentation  
    DARRT-1 Clinical Data Webinar  
    NOXOPHARM DARRT-1 Interview Dec 2, 2019  
    NOX 2019 AGM webcast  
    Noxopharm 2019 AGM Corporate Presentations  
    NOX and Nyrada TechKnow Invest Roadshow Presentations  
    Noxopharm looks at treating prostate cancer with Veyonda® in the LuPIN trial  
    NOX EGM Chairman's Address and Presentation  
    CEO Interview: Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment – DARRT-1 Interim Results  
    Noxopharm (ASX:NOX) 3-year listing anniversary update  
    Noxopharm August 2019 Corporate Presentation  
    Oral Presentation interim LuPIN-1 trial results given by Assoc. Professor Louise Emmett at SNMMI 2019 Annual Meeting, Anaheim CA  
    Noxopharm CEO & CMO Dr Greg van Wyk spoke recently with Karen Jagoda on the Empowered Patient Podcast about the increasing interest in combining therapies to treat prostate cancer as well as cancer types.  
    Noxopharm Corporate Presentation June 2019  
    Switzer Daily: How a biotech company could change cancer treatment  
    CEO Interview DARRT Program 6-month Interim Results  
    Noxopharm Ausbiotech Asia Series March 2019 Presentation  
    March 2019 Corporate Presentation  
    FNN - Shaw & Partners Investor Event 26.2.19  
    St Vincent's Hospital Principal Investigator Discussed LuPIN-1 Study  
    FNN interview with Nox Chief Medical Officer on Interim Data  
    2018 Annual General Meeting podcast  
    NOX 2018 AGM Presentations  
    Noxopharm Releases Latest Corporate Presentation  
    Noxopharm (ASX:NOX) Presentation, FNN Investor Event, 15 Aug 2018, Sydney  
    Noxopharm (ASX:NOX) update on NOX66 and radiotherapy trials  
    NOX Corporate Presentation FNN-Shaw&Partners Investor Event  
    Noxopharm Corporate Presentation for Public Briefing  
    Noxopharm CEO Interview Updates the Company's Current Research and Development Program  
    Noxopharm CEO Interview on near-completed NOX66 chemotherapy trial CEP-1  
    Noxopharm CEO Interview with FNN on the Company's NOX66 and Radiotherapy Clinical Programs  
    TROG Annual Scientific Meeting - Noxopharm Presentation 21.3.18  
    Corporate Presentation - Post Interim Clinical Data Release  
    Noxopharm CEO talks to FNN about CEP-1 Clinical Study Interim Data from 2018 TAT Congress in Paris, March 5-7  
    NOX Open Briefing Corporate Presentation  
    Noxopharm Limited 2017 AGM Webcast, November 27, 2017  
    AGM Presentations  
    EGM Presentations  
    October 2017 Open Briefing Corporate Presentation  
    Noxopharm Corporate Presentation for 2017 ASX Growth Series Conference, Singapore August 21  
    New Corporate Presentation  
    Noxopharm Mid- Year Briefing May 2017  
    New Corporate Presentation  
    Discovery of Idronoxil-C - NOX CEO explains  
    FNN Interview with NOX CEO Explaining Idronoxil-C Discovery  
    ASX The CEO Sessions - ASX Interview  
    ASX The CEO Sessions February 2017 Presentation  
    ASX CEO Presentation Feb 2017 slides  
    Upcoming Events and Presentations  
    Noxopharm (ASX:NOX) talks clinical trials and applications for ‘NOX66’  
    November 2016 Corporate Presentation  
    Corporate Presentation Providing Clinical Program Guidance  
    Corporate Presentation  
    Investor Roadshow Presentation